Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| AMPH | Amphastar Pharmaceuticals, Inc. | 2025-10-16 15:10:04 | 23.22 | 0 | 0 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AMPH | 0001297184 | Amphastar Pharmaceuticals, Inc. | US03209R1032 | 54930055TH0ZLSAQMJ38 | 330702205 | Nasdaq | 2834 | Pharmaceutical Preparations | 1231 | — | 11570 SIXTH STREET | RANCHO CUCAMONGA | CA | 91730 | UNITED STATES | US | 909-980-9484 | 11570 SIXTH STREET, RANCHO CUCAMONGA, CA, 91730 | 11570 SIXTH STREET, RANCHO CUCAMONGA, CA, 91730 | — | — | — | Jack Yongfeng Zhang | 1,615 | https://www.amphastar.com/ | 1,197,767,120 | 61,649,607 | 46,495,077 | Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products. | 2025-10-10 21:05:14 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 1,197,767,120 | -289,349,473 | -19.4571 | 47,650,121 | -445,741 | -0.9268 |
| 2023 | 1,487,116,593 | 601,855,576 | 67.9862 | 48,095,862 | 199,042 | 0.4156 |
| 2022 | 885,261,017 | 403,485,381 | 83.7496 | 47,896,820 | -250,045 | -0.5193 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Mary Ziping Luo | Chief Scientist, Chief Operating Officer, Chairman | 2024 | 746,038 | 314,723 | 1,265,495 | 163,000 | 43,930 | 3,798,698 |
| Rong Zhou | President, Executive Vice President | 2024 | 564,476 | 235,076 | 584,480 | 116,000 | 43,361 | 2,127,918 |
| Jack Yongfeng Zhang | Chief Scientific Officer, Director, President, Chief Executive Officer | 2024 | 915,308 | 317,078 | 3,001,991 | 444,000 | 54,357 | 7,734,759 |
| William J. Peters | Treasurer, Director, President, Chief Financial Officer, Executive Vice President | 2024 | 625,527 | 292,616 | 907,459 | 121,000 | 56,713 | 2,910,861 |
| Jacob Liawatidewi | President, Executive Vice President | 2024 | 480,789 | 220,375 | 501,997 | 75,000 | 41,576 | 1,821,762 |
| Fiscal Year | Employee Count |
|---|---|
| 2024 | 2,028 |
| 2023 | 1,761 |
| 2022 | 1,615 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 731,967,000 | 644,395,000 | 498,987,000 |
| Cost Of Revenue | 358,112,000 | 293,274,000 | 250,127,000 |
| Gross Profit | 373,855,000 | 351,121,000 | 248,860,000 |
| Research And Development Expenses | 73,914,000 | 73,741,000 | 74,771,000 |
| General And Administrative Expenses | 56,720,000 | 51,540,000 | 45,061,000 |
| Operating Expenses | 168,436,000 | 154,134,000 | 141,363,000 |
| Operating Income | 205,419,000 | 196,987,000 | 107,497,000 |
| Net Income | 159,519,000 | 137,545,000 | 91,386,000 |
| Earnings Per Share Basic | 3.29 | 2.85 | 1.88 |
| Earnings Per Share Diluted | 3.06 | 2.6 | 1.74 |
| Weighted Average Shares Outstanding Basic | 48,429,000 | 48,265,000 | 48,551,000 |
| Weighted Average Shares Outstanding Diluted | 52,058,000 | 53,001,000 | 52,427,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash And Cash Equivalents | 151,609,000 | 144,296,000 | 156,098,000 |
| Marketable Securities Current | 70,036,000 | 112,510,000 | 19,664,000 |
| Accounts Receivable | 136,289,000 | 114,943,000 | 88,804,000 |
| Inventories | 153,741,000 | 105,833,000 | 103,584,000 |
| Non Trade Receivables | 0 | 0 | — |
| Other Assets Current | — | — | — |
| Total Assets Current | 534,071,000 | 489,600,000 | 378,319,000 |
| Marketable Securities Non Current | 10,996,000 | 14,685,000 | — |
| Property Plant And Equipment | 297,345,000 | 282,746,000 | 238,266,000 |
| Other Assets Non Current | 25,992,000 | 25,910,000 | 20,856,000 |
| Total Assets Non Current | 344,627,000 | 894,662,000 | 264,573,000 |
| Total Assets | 1,577,470,000 | 1,512,912,000 | 741,987,000 |
| Accounts Payable | 30,514,000 | 25,438,000 | 20,501,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | 234,000 | 436,000 | 3,046,000 |
| Other Liabilities Current | 126,543,000 | 67,928,000 | 63,741,000 |
| Total Liabilities Current | 173,759,000 | 225,407,000 | 94,862,000 |
| Long Term Debt | 601,630,000 | 589,579,000 | 72,839,000 |
| Other Liabilities Non Current | 20,945,000 | 22,718,000 | 14,565,000 |
| Total Liabilities Non Current | 671,413,000 | 648,084,000 | 118,467,000 |
| Total Liabilities | 845,172,000 | 873,491,000 | 213,329,000 |
| Common Stock | 6,000 | 6,000 | 6,000 |
| Retained Earnings | 568,787,000 | 409,268,000 | 271,723,000 |
| Accumulated Other Comprehensive Income | -9,181,000 | -8,478,000 | -8,624,000 |
| Total Shareholders Equity | 732,298,000 | 639,421,000 | 528,658,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Depreciation And Amortization | 28,249,000 | 25,737,000 | 12,597,000 |
| Share Based Compensation Expense | 24,368,000 | 20,242,000 | 17,860,000 |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | 21,671,000 | 26,086,000 | 10,132,000 |
| Change In Inventories | 48,797,000 | 1,724,000 | 11,746,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | 63,563,000 | 13,237,000 | -736,000 |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | 213,386,000 | 183,503,000 | 89,181,000 |
| Purchases Of Marketable Securities | 76,792,000 | 144,556,000 | 35,761,000 |
| Sales Of Marketable Securities | 126,022,000 | 38,622,000 | 27,969,000 |
| Acquisition Of Property Plant And Equipment | 41,041,000 | 38,166,000 | 24,034,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -124,930,000 | -649,116,000 | -32,777,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | — | — | — |
| Repurchase Of Common Stock | 85,458,000 | 58,144,000 | 39,909,000 |
| Issuance Of Long Term Debt | — | 845,000,000 | — |
| Repayment Of Long Term Debt | 8,263,000 | 318,658,000 | 1,781,000 |
| Other Financing Activities | — | 10,974,000 | 15,658,000 |
| Cash From Financing Activities | -80,953,000 | 454,093,000 | -26,439,000 |
| Change In Cash | 7,313,000 | -11,802,000 | 29,745,000 |
| Cash At End Of Period | 151,609,000 | 144,296,000 | 156,098,000 |
| Income Taxes Paid | 40,104,000 | 49,001,000 | 44,442,000 |
| Interest Paid | 26,811,000 | 17,573,000 | 3,023,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Earnings Per Share | 3.29 | 2.85 | 1.88 |
| Price To Earnings Ratio | 11.2857 | 21.7018 | 14.9043 |
| Earnings Growth Rate | 15.4386 | 51.5957 | 44.6154 |
| Price Earnings To Growth Ratio | 0.731 | 0.4206 | 0.3341 |
| Book Value Per Share | 15.1211 | 13.2481 | 10.8887 |
| Price To Book Ratio | 2.4555 | 4.6686 | 2.5733 |
| Ebitda | 258,215,000 | 239,441,000 | 150,271,000 |
| Enterprise Value | 2,248,423,770 | 3,430,909,250 | 1,280,186,020 |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | 0.8219 | 0.9227 | 0.1435 |
| Capital Expenditures | 42,848,000 | 70,217,000 | 6,619,000 |
| Free Cash Flow | 170,538,000 | 113,286,000 | 82,562,000 |
| Return On Equity | 0.2178 | 0.2151 | 0.1729 |
| One Year Beta | 0.6487 | 0.803 | 0.4555 |
| Three Year Beta | 0.5478 | 0.5261 | 0.6714 |
| Five Year Beta | 0.678 | 0.7095 | 0.7073 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Petersen Floyd F. | Director | 2025-10-01 | 500 | D | 76,031 |
| Petersen Floyd F. | Director | 2025-09-02 | 500 | D | 76,531 |
| Petersen Floyd F. | Director | 2025-08-01 | 500 | D | 77,031 |
| Gaugh David Russell | Director | 2025-07-18 | 6,304 | A | 6,304 |
| Gaugh David Russell | Director | 2025-07-18 | 13,987 | A | 13,987 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| RICE HALL JAMES & ASSOCIATES, LLC | 2025-09-30 | 3,446,884 | 129,339 | 26.65 |
| City State Bank | 2025-09-30 | 3,998 | 150 | 26.6533 |
| Blue Trust, Inc. | 2025-09-30 | 47,117 | 1,768 | 26.6499 |
| CWM, LLC | 2025-09-30 | 40,000 | 1,508 | 26.5252 |
| Pacer Advisors, Inc. | 2025-09-30 | 159,793 | 5,996 | 26.6499 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| TRUST FOR PROFESSIONAL MANAGERS | 2025-08-31 | Column Small Cap Fund | CFSLX | 1,376 | 42,133.12 | 0.0088 |
| Pacer Funds Trust | 2025-07-31 | Pacer US Small Cap Cash Cows Growth Leaders ETF | CAFG | 2,136 | 44,749.2 | 0.2466 |
| Pacer Funds Trust | 2025-07-31 | Pacer US Small Cap Cash Cows ETF | CALF | 308,017 | 6,452,956.15 | 0.1612 |
| INVESCO EXCHANGE-TRADED FUND TRUST | 2025-07-31 | Invesco RAFI US 1500 Small-Mid ETF | PRFZ | 35,738 | 748,711.1 | 0.0316 |
| CALAMOS INVESTMENT TRUST/IL | 2025-07-31 | Class R6 | CVSOX | -30,580 | -640,651 | -0.0039 |